This international Delphi survey seeks to develop expert consensus to guide the management of MET inhibitor-associated peripheral edema in patients with advanced/metastatic NSCLC harboring MET alterations (MET exon 14 skipping mutations, MET amplification, MET fusions), or MET overexpression.
Peripheral edema is a common class effect of MET inhibitors, with grade ≥3 events occurring in some patients. It significantly impacts patient quality of life and can lead to dose reductions or treatment discontinuation, potentially compromising outcomes.
Despite its clinical importance, standardized management guidance is lacking. Current approaches – including lifestyle modifications, compression therapy, diuretics, and empirical dose adjustments - vary among clinicians.
This survey uses the Delphi methodology1 to establish expert consensus recommendations to help optimize care for patients with NSCLC harboring MET alterations receiving MET inhibitors.
You are invited to complete a 20-question online questionnaire (maximum duration 15 minutes). This survey is intended for healthcare professionals experienced in managing patients with advanced/metastatic NSCLC harboring MET alterations who develop MET inhibitor-related peripheral edema.
No preparatory work is required, and there are no right or wrong answers. We seek your overall clinical experience and insights - not patient-level data or record review.
The Delphi method is iterative. After Round 1, you will be invited to participate in survey Round 2 (summer 2026), which will focus on topics requiring clarification. You will receive aggregated Round 1 results to inform your responses.
All responses are anonymous and confidential. Only aggregated data will be analyzed and reported.
Thank you for your valuable contribution to this collaborative initiative.
On behalf of the Steering Committee
Prof. Frank GRIESINGER
Pius-Hospital; University Medicine of Oldenburg, Oldenburg, Germany.
Dr. Terufumi KATO
Department of Thoracic Oncology, Kanagawa Cancer Center, Yokohama-shi, Japan.
Dr. Claudio MARTIN
Alexander Fleming Institute; Hospital Maria Ferrer, Buenos Aires, Argentina.
Dr. Paul PAIK
Memorial Sloan Kettering Cancer Center, New York; Weill Cornell Medical College, New York, United States.
Prof. Giulia PASELLO
University of Padova; Institute Oncology Veneto, Padova, Italy.
Prof. Daniel TAN
National Cancer Center Singapore, Singapore.
This Delphi survey is conducted by Public Health Expertise (PHE), Paris, France and funded by Merck (CrossRef Funder ID: 10.13039/100009945). If you have any questions, please contact: myriam.chebbah@cencora.com. PHE - 10 boulevard de Sébastopol, 75004 Paris, France.
The email provided for registration and any other personal data will be deleted once the questionnaire is closed. The sponsor will not have access to any personal data.
1 Niederberger, M. & Spranger, J. Delphi Technique in Health Sciences: A Map. Front Public Health 8, 457 (2020).
We comply with applicable national and regional laws and regulations on personal data protection in the countries involved in this project (Europe, the Americas, Asia and the Middle East, and Oceania), and we adhere to relevant professional codes of conduct and ethics, including ASOCS, ESOMAR and EphMRA.
This includes, where applicable:
The purpose of this questionnaire is solely to gather your opinions and has no promotional intent. No one will attempt to sell you anything. All information you provide will remain confidential and will be analyzed and presented only in aggregated form, without any information that could identify you. You may withdraw from the study at any time and/or choose not to disclose certain information.
Thus, the collection, use, storage, and disclosure of your personal information are managed as indicated below.
Public Health Expertise (Myriam Chebbah, myriam.chebbah@cencora.com) will act as the controller of data. The personal information you enter in this registration form will not be shared.
In accordance with the data protection law from Europe, Americas, Asia and Middle East, Oceania, we inform you that we only collect and process personal data necessary for the study.
Personal data collected during the survey will be kept for the duration of the study (approximately 6 months) and then deleted. Therefore, we will not be able to identify information about you if you send us an access request once the study is completed.
Be assured that we make every effort to ensure the security and confidentiality of your personal data.
The personal information collected in this project includes your name, email address, and place of practice.
Your personal data is collected to send you an email containing the link to access this online questionnaire and a reminder email in case of partial completion of the questionnaire, if applicable.
We commit to not selling, sharing, or distributing your personal information in any way to third parties, except as provided in this Privacy Policy.
You can request information about this project, the collection of your data, and exercise your rights of access, rectification, deletion, limitation, and opposition to the processing of your data by contacting Myriam Chebbah: myriam.chebbah@cencora.com